Anuh Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹194Cr
- +4.3% YoY
- −4% QoQ
- Net profit
- ₹11Cr
- +37.5% YoY
- −8.3% QoQ
- Margin
- 8%
- +2 pp YoY
- −2 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Anuh Pharma Ltd Q1 FY27 key numbers
- Revenue
- Operating Profit: Rs. 38.15 Cr, up 39.50% YoY.
As stated in Anuh Pharma Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Anuh Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8). EBITDA for Q1 FY27: Rs. 19.36 Cr, a 41.56% increase YoY; EBITDA margin: 9.99% vs. 7.34% in Q1 FY26.
From Anuh Pharma Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8).
- Production Volume: 491 MT, up 19.46% YoY from 411 MT in Q1 FY26 (Page 6).
- Operating Profit: Rs. 38.15 Cr, up 39.50% YoY (Page 8).
- Revenue by Product Groups and Customers: Detailed product-wise revenues and customer concentration referenced but specific figures focus on totals only for Q1 FY27 vs Q1 FY26 (Pages 10-13).
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement."
- Growth strategy includes "extensive volume expansions across API lines."
- Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq. m) with 9 API blocks and 2 intermediate blocks; 10,000 sq. ft. R&D facility at Mahape, Navi Mumbai, DSIR approved.
2 more points from Anuh Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 194 | 186 | +4.3% | 202 | -4% |
| Operating profit (EBITDA) | 16 | 10 | +60% | 20 | -20% |
| Operating margin | 8% | 6% | +2 pp | 10% | -2 pp |
| Profit before tax | 17 | 11 | +54.5% | 16 | +6.3% |
| Net profit (PAT) | 11 | 8 | +37.5% | 12 | -8.3% |
| EPS (₹) | 1.14 | 0.83 | +37.3% | 1.17 | -2.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY27 results?
Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8). EBITDA for Q1 FY27: Rs. 19.36 Cr, a 41.56% increase YoY; EBITDA margin: 9.99% vs. 7.34% in Q1 FY26.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
- Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement." - Growth strategy includes "extensive volume expansions across API lines." - Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
